GlobeNewswire

Baylor Genetics to Highlight the Clinical Value of Genomics in Pediatric Care at the 2026 National Society of Genetic Counselors Annual Meeting
09/11/2026
Two new data presentations underscore the diagnostic and clinical utility of genome and exome sequencing for pediatric patients with hearing loss and immunodeficiency HOUSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Baylor [...]
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
09/11/2026
CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T [...]
Kraig Labs Ships Spider Silk to Developers Across Global Industries
09/11/2026
A Global Apparel Pilot and Shipment to a Materials Innovator with Aerospace Experience Put Customer Feedback in Focus DENVER, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews )—Kraig Biocraft Laboratories ( OTCQB: KBLB [...]
Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardiometabolic benefits
09/11/2026
Company announcement – No. 55 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 [...]
Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase III SYNCHRONIZE-CVOT trial alongside significant cardiometabolic benefits
09/11/2026
SYNCHRONIZE-CVOT met its primary endpoint demonstrating the safety of survodutide in terms of major adverse cardiovascular events compared with placebo in people with obesity and established cardiovascular disease (CVD [...]
Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
09/11/2026
Single-cell sequencing demonstrates pelareorep’s ability to remodel the tumor microenvironment in a hematological cancer SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics [...]
Oncovita Granted Orphan Drug Designation For MVdeltaC in Mesothelioma by the European Commission
09/11/2026
Following FDA orphan drug designation in 2025, the European decision marks a further milestone as Oncovita prepares to initiate clinical development in late 2027 The European Commission granted orphan designation on [...]
USARAD, a Nanox Company, Expands Collaboration with AZmed to Integrate FDA-Cleared X-ray AI into Its Teleradiology Workflows
09/11/2026
AZmed's FDA-cleared, clinically validated X-ray AI suite to be integrated into USARAD's workflows through Nanox Marketplace Expansion builds on USARAD's existing use of AZmed AI, from acute trauma to chest X-rays, to [...]
CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
09/11/2026
-Data presented in a late-breaking oral presentation at AHA- -A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) at Day 30 in [...]
Park Dental Partners Completes Acquisition of Village Family Dental Support Services Organization, Expands into North Carolina
09/11/2026
MINNEAPOLIS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK) (the “Company”), a leading dental resource organization, announced that it completed its acquisition of the Village Family Dental [...]
Curia augmente sa capacité de fermentation à León, en Espagne
09/11/2026
Cet investissement de 5 millions d’euros renforcera les opérations de fermentation et de traitement en aval ALBANY, New York, 09 nov. 2026 (GLOBE NEWSWIRE) -- Curia Global Inc. (Curia), une organisation mondiale de [...]
Curia Expands Fermentation Capacity in León, Spain
09/11/2026
The 5-million-euro investment will strengthen fermentation and downstream processing operations ALBANY, N.Y., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Curia Global Inc. (Curia), a global contract research, development and [...]
Cannabix Technologies Announces Detection of Fentanyl in Human Breath
09/11/2026
Successful detection of fentanyl in human breath marks a significant technical milestone VANCOUVER, British Columbia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: [...]
NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues
09/11/2026
DALLAS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ( www.InvestorsTape.com ) — NeOnc Technologies Holdings (NASDAQ:NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares of the company's common stock for approximately $ [...]
Vireo Growth Inc. Completes Acquisition of FLUENT Corp.
09/11/2026
Transaction further strengthens Vireo’s position in Florida and adds FLUENT’s Buffalo, New York operations MINNEAPOLIS and TAMPA, Fla., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) (“ [...]
Biodexa provides R&D Update
09/11/2026
November 9, 2026 Biodexa provides R&D Update Phase 3 Serenta trial in FAP is now two-thirds recruited Preparations advanced for Phase 1 trial of MTX240 in GIST Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” [...]
Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026
09/11/2026
MIAMI, FL, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, [...]
Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
09/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical biomarker analyses related [...]
Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200
09/11/2026
Boys Town National Research Hospital in Nebraska becomes first activated site in study targeting four rare pediatric lysosomal storage disorders and has now initiated patient screening as Polaryx advances toward first [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum